13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
28 檔
77.8%
According to the latest 13F quarterly dataset, 5AM Venture Management, LLC managed an equity portfolio of $287.9M at the end of Q3 2024, spanning 28 distinct U.S. exchange-listed positions.
5AM Venture Management, LLC executed strategic sector rebalancing during Q3 2024, establishing 1 new positions while fully exiting 1 holdings and trimming 4 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TRDA | Entrada Therapeutics Inc | Stock-Other | 14.55% | -3.84% | — | |
| 2 | ELVN | Enliven Therapeutics Inc | Stock-Other | 9.25% | — | -32.89% | |
| 3 | SKYE | Skye Bioscience Inc | Stock-Other | 8.01% | +0.68% | -2.62% | |
| 4 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 7.51% | +3.72% | — | |
| 5 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 6.97% | — | -0.11% | |
| 6 | BHVN | Biohaven Ltd. | Stock-Other | 4.95% | +2.08% | +1.92% | |
| 7 | TYRA | Tyra Biosciences Inc | Stock-Other | 4.56% | +0.48% | — | |
| 8 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.25% | -6.41% | EXIT | |
| 9 | TECX | Tectonic Therapeutic Inc | Stock-Other | 4.05% | +2.03% | — | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.04% | — | — | |
| 11 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.49% | +2.05% | — | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.46% | — | — | |
| 13 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 3.11% | — | — | |
| 14 | PHVS | Pharvaris N.V. | Stock-Other | 3.05% | +3.32% | — | |
| 15 | ERAS | Erasca Inc | Stock-Other | 3.05% | -15.66% | EXIT | |
| 16 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.94% | — | — | |
| 17 | ANAB | Anaptysbio Inc | Stock-Other | 2.48% | — | — | |
| 18 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.79% | +1.12% | — | |
| 19 | EYPT | Eyepoint Inc | Stock-Other | 1.73% | +1.46% | +2000.00% | |
| 20 | COGT | Cogent Biosciences Inc | Stock-Other | 1.25% | — | -28.92% | |
| 21 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.13% | — | — | |
| 22 | VOR | Vor Biopharma Inc. | Stock-Other | 0.92% | — | — | |
| 23 | ✓ | Rallybio CORP | Stock-Other | 0.88% | — | — | |
| 24 | GHRS | GH Research PLC | Stock-Other | 0.79% | -2.24% | EXIT | |
| 25 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.79% | — | — | |
| 26 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.51% | — | — | |
| 27 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.37% | +4.09% | — | |
| 28 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.13% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ARTV | Artiva Biotherapeutics Inc | +7.5% | NEW | New buy |
| 2 | 260 | Centessa Pharmaceuticals-adr | +1.7% | +3.21% | Add |
| 3 | TECX | Tectonic Therapeutic Inc | +1.7% | — | Unchanged |
| 4 | EYPT | Eyepoint Inc | +1.6% | +2000.00% | Add |
| 5 | VRDN | Viridian Therapeutics Inc | +1.3% | — | Unchanged |
| 6 | BHVN | Biohaven Ltd. | +1.3% | +1.92% | Add |
| 7 | TYRA | Tyra Biosciences Inc | +1.2% | — | Unchanged |
| 8 | PRAX | Praxis Precision Medicines I | +0.9% | — | Unchanged |
| 9 | TRDA | Entrada Therapeutics Inc | +0.5% | — | Unchanged |
| 10 | ANAB | Anaptysbio Inc | +0.5% | — | Unchanged |
| 11 | VKTX | Viking Therapeutics Inc | +0.3% | — | Unchanged |
| 12 | ERAS | Erasca Inc | +0.2% | — | Unchanged |
| 13 | MLTX | Moonlake Immunotherapeutics | +0.2% | — | Unchanged |
| 14 | CDTX | Cidara Therapeutics Inc | 0% | — | Unchanged |
| 15 | SCPH | Scpharmaceuticals Inc | 0% | — | Unchanged |
| 16 | AVU0 | Adverum Biotechnologies Inc | 0% | — | Unchanged |
| 17 | ZNTL | Zentalis Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 18 | ✓ | Mersana Therapeutics Inc | -0.1% | — | Unchanged |
| 19 | DNTH | Dianthus Therapeutics Inc | -0.2% | -0.11% | Trim |
| 20 | ✓ | Rallybio CORP | -0.2% | — | Unchanged |
| 21 | SLN | Silence Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 22 | COGT | Cogent Biosciences Inc | -0.2% | -28.92% | Trim |
| 23 | PHVS | Pharvaris N.V. | -0.3% | — | Unchanged |
| 24 | VOR | Vor Biopharma Inc. | -0.5% | — | Unchanged |
| 25 | CLDX | Celldex Therapeutics Inc | -0.6% | — | Unchanged |
| 26 | GHRS | GH Research PLC | -0.7% | — | Unchanged |
| 27 | QTTB | Q32 Bio Inc | -1% | EXIT | Sold out |
| 28 | ELVN | Enliven Therapeutics Inc | -4.4% | -32.89% | Trim |
| 29 | SKYE | Skye Bioscience Inc | -10.2% | -2.62% | Trim |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 28 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TRDA, ELVN, SKYE) accounted for 77.8% of total reported equity market value during Q3 2024.
Top New Position Initiated
ARTV
市值: $36.4M
Top Position Liquidated / Trimmed
QTTB
前期市值: $4.5M
During Q3 2024, 5AM Venture Management, LLC's top holdings by market value included TRDA (14.6%)、ELVN (9.3%)、SKYE (8.0%). The largest single position, TRDA, represented 14.6% of total portfolio value.
In Q3 2024, 5AM Venture Management, LLC made 9 total portfolio adjustments, initiating 1 new buys, adding to 3 positions, trimming 4 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.